vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid, akut - antineoplastiska medel - behandling av akut myeloisk leukemi.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
xalkori
pfizer europe ma eeig - crizotinib - carcinom, non-small cell lung - antineoplastiska medel - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
alecensa
roche registration gmbh - alectinibhydroklorid - carcinom, non-small cell lung - antineoplastiska medel - alecensa som monoterapi är indicerad för förstahandsbehandling av vuxna patienter med anaplastisk lymfomkinas (alk) -positiv avancerad icke-småcellig lungcancer (nsclc). alecensa som monoterapi är indicerat för behandling av vuxna patienter med alk‑positiv avancerad icke småcellig lungcancer som tidigare har behandlats med crizotinib.
alunbrig
takeda pharma a/s - brigatinib - carcinom, non-small cell lung - antineoplastiska medel - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
zykadia
novartis europharm limited - ceritinib - carcinom, non-small cell lung - antineoplastiska medel - zykadia är indicerat för behandling av vuxna patienter med anaplastisk lymfomkinas (alk) positiv, avancerad, icke-småcellad lungcancer (nsclc) som tidigare behandlats med crizotinib.
prograf 0,5 mg kapsel, hård
cross pharma ab - takrolimus (vattenfri) - kapsel, hård - 0,5 mg - takrolimus (vattenfri) 0,5 mg aktiv substans; laktos (vattenfri) hjälpämne - takrolimus
prograf 1 mg kapsel, hård
paranova läkemedel ab - takrolimus (vattenfri) - kapsel, hård - 1 mg - takrolimus (vattenfri) 1 mg aktiv substans; laktos (vattenfri) hjälpämne - takrolimus
prograf 1 mg kapsel, hård
omnia mutantur läkemedel ab - takrolimus (vattenfri) - kapsel, hård - 1 mg - takrolimus (vattenfri) 1 mg aktiv substans; laktos (vattenfri) hjälpämne - takrolimus